Cargando…

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series

BACKGROUND. Posttransplant fertility returns quickly, and female recipients of child-bearing age may conceive while on immunosuppression. However, pregnancy after transplantation confers risks to the recipient, transplant, and fetus, including gestational hypertension, preeclampsia, gestational diab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coscia, Lisa, Cohen, David, Dube, Geoffrey K., Hofmann, R. Michael, Moritz, Michael J., Gattis, Sara, Basu, Arpita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Clinical Science—General
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442140/ https://www.ncbi.nlm.nih.gov/pubmed/37287109 http://dx.doi.org/10.1097/TP.0000000000004634

Ejemplares similares

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Acute kidney injury during pregnancy in kidney transplant recipients
por: Yadav, Anju, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

2702. A Case Series of Kidney Transplant Recipients on Belatacept with CMV Infection in a Single Academic Center
por: Feller, Fionna, et al.
Publicado: (2023)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
por: Gupta, Shruti, et al.
Publicado: (2018)

Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature
por: Deliège, Pierre-Guillaume, et al.
Publicado: (2020)

Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept
por: Chavarot, Nathalie, et al.
Publicado: (2021)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant
por: Manook, Miriam, et al.
Publicado: (2023)

Immune Response Post–SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept
por: Noble, Johan, et al.
Publicado: (2021)

Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept
por: Choi, Mira, et al.
Publicado: (2020)

Ten Years Experience With Belatacept-Based Immunosuppression After Kidney Transplantation
por: Grannas, Gerrit, et al.
Publicado: (2014)

Belatacept in Kidney Transplantation: What Are the True Benefits? A Systematic Review
por: Lombardi, Yannis, et al.
Publicado: (2022)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy
por: Morel, Antoine, et al.
Publicado: (2022)

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
por: Bredewold, Obbo W., et al.
Publicado: (2022)

Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high‐risk cytomegalovirus serostatus kidney transplant recipients
por: Magua, Wairimu, et al.
Publicado: (2022)

Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
por: Gouin, Anna, et al.
Publicado: (2020)

Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
por: Vincenti, F., et al.
Publicado: (2017)

Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept
por: Pernin, Vincent, et al.
Publicado: (2022)

Factors Associated With Reduced Anti-SARS-CoV-2 Antibody Responses After mRNA Vaccination in Kidney Transplant Recipients on Belatacept
por: Morena, Leela, et al.
Publicado: (2022)

Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: de Graav, Gretchen N., et al.
Publicado: (2017)

Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation
por: Zhang, Hengcheng, et al.
Publicado: (2021)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens
por: Ashokkumar, Chethan, et al.
Publicado: (2015)

Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
por: Belliere, Julie, et al.
Publicado: (2014)

Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: Schroder, Paul M., et al.
Publicado: (2017)

Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction
por: Gallo, Ester, et al.
Publicado: (2020)

Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France
por: Bertrand, Dominique, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tnamc7ahoh9enr1lfa9t69mnb0